Proteros announced that it signed a research cooperation agreement with Bayer aimed at identifying new agents for the treatment of cardiovascular diseases. Under the agreement, Proteros will be carrying out the research on a regulating membrane protein over a period of two years in order to achieve defined milestones, while Bayer will be responsible for the optimisation of pre-clinical candidates and clinical development. Proteros will receive payments for its R&D activities as well as milestone payments and royalties from the sale of potential commercial products.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
25.89 EUR | -0.64% | -0.57% | -22.76% |
11:34am | Bayer: new positive data for Nubeqa | CF |
10:44am | Bayer with trial success in prostate cancer - Analyst: As expected | DP |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-22.76% | 27.86B | |
+61.53% | 848B | |
+33.30% | 627B | |
-3.66% | 363B | |
+15.06% | 318B | |
+9.18% | 299B | |
+12.39% | 234B | |
+16.21% | 225B | |
+15.67% | 179B | |
+2.47% | 167B |
- Stock Market
- Equities
- BAYN Stock
- News Bayer AG
- Proteros Signs Research Cooperation Agreement with Bayer